Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

cancer diagnostics

  • Home
  •  
  • cancer diagnostics



  • Most Read
  • Latest Comments
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch
    CLEO meets with US FDA to develop strategy for ovarian cancer test launch
    • News

  • Cleo’s ovarian cancer blood test proves more effective than CA125 clinical benchmark and ultrasound
    Cleo’s ovarian cancer blood test proves more effective than CA125 clinical benchmark and ultrasound
    • News

  • Cleo Diagnostics progresses ovarian cancer test kits for US, Australia, and EU markets
    Cleo Diagnostics progresses ovarian cancer test kits for US, Australia, and EU markets
    • News

  • IPO Watch: Cleo Diagnostics to go public with ovarian cancer test kits to address 51% survival rate
    IPO Watch: Cleo Diagnostics to go public with ovarian cancer test kits to address 51% survival rate
    • News

  • Rhythm Biosciences nears commercialisation of revolutionary cancer test following filing of approval documents with the TGA
    Rhythm Biosciences nears commercialisation of revolutionary cancer test following filing of approval documents with the TGA
    • News

  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch
    • News

    CLEO meets with US FDA to develop strategy for ovarian cancer test launch

    Ovarian cancer diagnostics company Cleo Diagnostics (ASX: COV) has taken a major step towards the US launch of its pre-surgical triage test for ovarian cancer detection. The Company wrapped up an initial pre-submission meeting with the U.S. Food and Drug Administration (FDA), thus setting its regulatory journey in motion. Ovarian cancer is a serious health

    Read More
    Public
  • Rhythm Biosciences nears commercialisation of revolutionary cancer test following filing of approval documents with the TGA
    • News

    Rhythm Biosciences nears commercialisation of revolutionary cancer test following filing of approval documents with the TGA

    Rhythm Biosciences (ASX: RHY) is a step closer to commercialising their bowel cancer detection test, having submitted documents to the Australian Therapeutic Goods Administration (TGA) for approval. The filing is a significant milestone for the Company who are hoping to launch their product to market later this year.  Rhythm’s test offers a convenient and non-invasive

    Read More
    Public
  • Theranos, but make it legit.. Does this company have the answer to cancer detection via blood test?
    • News

    Theranos, but make it legit.. Does this company have the answer to cancer detection via blood test?

    Treating cancer is a primary goal of many biotech companies, but for any treatment to begin, physicians need a definitive diagnosis. We know that time is critical in disease diagnosis and initiating treatment sooner translates to better patient outcomes more often than not. The field of diagnostics is the yin to medical treatment’s yang. They

    Read More
    Public
  • Universal Biosensors partners with Peter Mac for handheld cancer diagnosis device
    • News

    Universal Biosensors partners with Peter Mac for handheld cancer diagnosis device

    A handheld device which can remotely diagnose the presence of cancer cells is on the horizon with biotech company Universal Biosensors (ASX: UBI) partnering with the Peter MacCallum Cancer Centre on the project.  Under the agreement, Peter Mac will supply cancer patient samples to Universal Biosensors which will use the plasma samples in their trials

    Read More
    Public
  • How BCAL Diagnostics is improving minimally invasive methods of early cancer detection
    • News

    How BCAL Diagnostics is improving minimally invasive methods of early cancer detection

    With 1 in 7 Australian women diagnosed with breast cancer, the demand for a minimally invasive, accurate diagnostic test is growing. Whilst health professionals recommend bi-annual breast screening for women aged 50-74, the invasive nature of imaging and ultrasound techniques leads to low compliance. There is well documented evidence that early cancer detection markedly improves

    Read More
    Public
  • Truscreen expands market for real time digital diagnostic testing device
    • News

    Truscreen expands market for real time digital diagnostic testing device

    Ahh the pap smear. The daunting, uncomfortable and downright annoying process of having a cervical swab taken to be tested for cancerous or precancerous cells, only to be repeated in 3-5 years time.  Despite being an important aspect of women’s health – COVID-19, uncomfortable gyno appointments, and misinformation means that booking in for that test

    Read More
    Public
  • 1
  • 2

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.